Alternative explanations for development of late-onset neutropenia in rituximab-treated rheumatic disease patients: comment on the article by Tesfa et al

Arthritis Rheum. 2012 Feb;64(2):596-7; author reply 597. doi: 10.1002/art.33428.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / adverse effects*
  • Antirheumatic Agents / adverse effects*
  • B-Lymphocytes*
  • Humans
  • Neutropenia / chemically induced*
  • Rheumatic Diseases / drug therapy*

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents